Successful pregnancy in a severe hypertensive patient treated with nitrendipine. Case report.

José A. Colina-Chourio 1, Nereyda Godoy 2, María Olveros-Palacios 2, María Nery-Villarroel 3, Ildefonso Aracha 4.

1Cátedras de Fisiología, 2Clínica Médica y Obstetricia, Facultad de Medicina, Universidad del Zulia and Renal Service and Laboratory Hospital Universitario de Maracaibo; 3Bayer de Venezuela S.A., Caracas, Venezuela.

Key words: hypertension, pregnancy, calcium antagonists.

Abstract. Nitrendipine (NIT), a new potent calcium channel blocking agent, was administered to a patient with essential severe (191/119 mm Hg), refractory, and resistant hypertensive (HT) to conventional triple drug regime. Three previous pregnancies had been unsuccessful in the past 4 years because of uncontrollable HT and repeated hypertensive crises. NIT (20 mg tablets) was given PO as a single morning dose and 15 months after BP control, she became pregnant again. With a 20 mg/day dose of NIT throughout pregnancy, a healthy 2400 g, 47 cm male boy was delivered by a non-emergency cesarean section at 37 weeks’ pregnancy. Both mother and son remain normal months after birth. The results suggest NIT may be considered as an alternative for this type of patients and should be studied in clinical trials.

MATERIALS AND METHODS

Case report.

N. de P., a 34-year old Executive Secretary gravida 3, was a known severe hypertensive patient that was referred to the University Hospital’s Hypertension Clinic because of severe, resistant, and refractory essential HT difficult to control (8) and with repeated hypertensive crises (1 to 3 per month). Her BP values were variable between 180/155 to 220/130 mm Hg (191.5 ± 4.33/119.5 ± 3.6 mm Hg, M ± SEM, n = 6, fig. 1). She was being treated with a triple drug regime consisting of propranolol, hydralazine and furosemide; previously she had received thiazide diuretics and ACEI (captopril and enalapril) all in adequate dosage and compliance but having either intolerance or ineffectiveness. She had a history of 3 lost pregnancies in the past 4 years: two 18th and 19th weeks fetal losses and a 32-week neonatal dead girl, all related to high BP values and hypertensive crises with severe emotional distress for both parents; during these pregnancies she received both antihypertensive, dietetic and strong psychological and psychiatric care as it was during the present pregnancy. Placental ischaemia was demonstrated in all 3 cases, consisting of vascular sclerosis, lipomatosis and thickening, placental low weight and infarct areas both whitish and hemorrhagic. She had severe HT with grade II retinal fundoscopy and deeply depressed but was otherwise in apparent good health with normal renal function and ECG. Psychiatric help was obtained throughout the follow-up period and thereafter, in the same way as it was during the previous 3 lost pregnancies. Secondary forms of HT and any other systemic disease were ruled out. A full gynaecological and ultrasonographic evaluation showed no breast tumors, a normal Pap smear and a nodular uterine’s anterior wall leiomyomatata that was asymptomatic.

Because of the severity of her HT, her low plasma renin activity of 0.4 ng/ml/h (11) (normal values in our laboratory = 0.27-2.7 (14)), the apparent lack of success of ACEI and other antihypertensive drugs in controlling her high BP (10,18), and the reported efficacy of CCBA (especially NIT) in mild to moderate and severe HT (1, 2, 3, 5, 7, 10, 12, 20), NIT was chosen for her treatment and administered as a single morning 40 mg/day oral dose; her BP could then be controlled and maintained at varying levels between 150/80 and 130/75 mm Hg (Fig. 1) presenting...
light tolerable throbbing headache and facial redness.

BP at an average of 120/70 mm Hg throughout pregnancy and imme-

Fig. 1. Hemodynamic course and nitrendipine effect on the patient.

Pregnancy and outcome.

Fifteen months after satisfactory hemodynamic control and highly anxious to have her own child - since she strongly refused adoption - she became pregnant for the fourth time (Fig. 1). After approval from the ethics committee of our Hospital and both patient and husband's written consent, NIT was continued at the same dosage maintaining BP values at an average of 120/70 mm Hg and heart rate of 84 per min, presenting mild ankle edema every week of 10th of gestation. At week 12th of gestation this dose had to be reduced to 20 mg/day because of mild symptoms of hypotension and low BP values (80/45 mm Hg, Fig. 1). This new dose was sufficient to keep her

ate post-partum period without noticeable side effects (Fig. 1). Renal function was unchanged and fetal distress was not observed.

During pregnancy BP (measured all the time with an automatic cuff) and body temperature and weight were measured daily. Renal and liver functions and ECG as well as general being were checked every 2 weeks, and every week in the last trimester. Routine obstetric and psychiatric care took place every week from the beginning and additional check-ups were made if necessary. Ultrasonographic controls and cardiotocography were performed at each obstetric examination after the 10th week of pregnancy showing no fetal distress and confirming the uterine myoma. The fetal heart rate records were normal as were the Doppler velocity waveforms of the umbilical arteries. All patients' tests remained normal as well as fetal growth and amniotic fluid.

She was admitted to the hospital at week 12th of gestation because of mild vomiting and enhanced anxiety, and was discharged 3 weeks later after appropriate support and treatment. There were no changes in either mother's or fetus' evolution and she was in good and stable conditions. Because uric acid was raising, the patient had increasing anxiety with emotional distress, and the presence of an uterine leiomyomata, a non-emergency elective lower-segment cesarean section was performed at 37 weeks' gestation under peridural anaesthesia 4 hours after that day's NIT dose: an apparently healthy 2400 g, 47 cm male infant was delivered without complications on July 29th, 1988. The baby had an Apgar score of 8 and 9 at 1 and 5 min respectively, did not require respiratory support, voided urine spontaneously, and the examination showed no evidence of congenital anomalies, a normal biochemical and hematological profile, including arterial, urinary and acid-base parameters, and had an uncomplicated course in the nursery. The placenta weighed 300 g and was grossly and histologically normal. Amniotic fluid was thought to be less than normal but was not measured. Mother and son remain in good health 48 months after delivery. The patient's BP values remain stable at 130/80 mm Hg with a 20 mg/day single oral dose of NIT (Fig. 1) and the child, under pediatric care, has had a normal physical, emotional and intellectual development to date, as judged from his clinical, hematological and biochemical evaluations, his normal growth rate and physical-psychological evaluations. The absence of any pathological situation and the fact that he is in kindergarten school performing as any other child in class.

The child was breast-fed for 6 months after birth. It was observed on several occasions that 90 to 120 min after breast-feeding he had mild facial redness and warmth, which are attributed to calcium antagonists' vasodilatory effect.

DISCUSSION

Outside pregnancy, severe HT difficult to control is a serious situation, and within pregnancy it places additional burden (4, 15, 20) so that the association of severe HT and pregnancy is subject of continued concern since it produces both maternal morbidity-mortality and high perinatal mortality. Although major emphasis is placed on the benefit of the fetus, maternal physical and emotional needs may be equally important, as illustrated in our case where additional concern was produced by the emotional weight imposed on both parents: she was in her mid-thirties and had had 3 previous pregnancy losses so far.

Although references are scarce, the availability of potent and safe vasodilator drugs suggests that the severe and/or refractory HT may be controlled (2, 3, 7, 10, 18), the favorable evolution and successful outcome of a pregnancy associated with severe HT seems possible nowadays.
Nitrendipine in pregnancy

Thus, it may be highly advisable for the patient to obtain a safe and stable BP control in order to become pregnant again as illustrated in this case (Fig. 1). After that, the severe hypertensive pregnant woman should be supported to provide continued and vigorous BP, somatic and emotional normal functioning and control and therefore, the potential for development and growth of her fetus.

The drug choice for treatment should be one of potent vasodilator properties (1, 4, 7, 10, 15, 16, 20) that ensures a successful pregnancy and the output of a normal child. It involves both the hemodynamic stability of the mother and the utero-placental circulation. The utero-placental vasculature is normally responsive to α-adrenergic stimulation (9), and on the other hand, in newborns, arterial pressure is low and renal autoregulation might be warranted by the highly activated renin-angiotensin system (13). The severe increase in systemic vascular resistance associated with the HT is consistent with the anticipated vasocostriction that might decrease utero-placental blood flow and jeopardize the fetus; thus, it seems more reasonable and convenient to cause a direct decrease in systemic vascular resistance than an indirect one and maintain the renin-angiotensin system activated. In such conditions, ACEI do not seem adequate enough and additionally, neonatal anuria has been described after administration of captopril (16) and enalapril (17) during pregnancy. On the contrary, CCBA may provide several advantages in this type of situation. They are among the most useful antihypertensive drugs for the treatment of HT with associated diseases and difficult to control (1, 2, 3, 7, 10, 18); both verapamil (15) and nifedipine (20) have appeared safe and effective in the control of BP values in patients with HT associated with pregnancy (4). CCBA may activate the renin-angiotensin system (2, 3, 12) and interfere with the reflex increase in sympathetic activity and α-adrenergic-mediated vasoconstriction (6) in the umbilical arteries (9) by their α-adrenergic inhibitory action (19). Also, the magnitude of BP reduction appears to be directly related to pretreatment BP values and inversely related to pretreatment renin values (2, 11), which this patient had. Moreover, there is no reported evidence of mutagenesis, carcinogenesis, or teratogenicity associated with the use of either NIT or CCBA so far and NIT is pharmacologically a more convenient drug than the preexisting CCBA available (1, 2, 5, 7, 10, 12, 18).

For all the aforementioned data, the characteristics of NIT, the fact that this particular patient had been on a previous mult.drug antihypertensive regime (3, 18) including ACEI, that failed to control her high BP, and the potential benefits on a possible future fetus (12, 16, 17, 20), we decided to treat her with NIT and to continue with it once pregnancy occurred. In this case, NIT was able to reduce BP satisfactorily in a patient with HT difficult to control (2, 3, 7, 8, 10, 18) and under its effects, pregnancy was straightforward with no threatening events apart from her constant apprehension of losing her probable last chance of having her own child, according to her own conviction. Delivery was prompted mainly by her emotional instability and the increasing levels of uric acid.

The issue of costs was also important within the context of the requirements for extra care and management. Nevertheless, both the parents and medical staff consider it justifiable and highly rewarding in view of the final outcome. Too few cases - if any - have been previously reported in this situation to evaluate the rate at which NIT or CCBA may help to provide sustained non-complicated pregnancies with healthy newborns in patients with severe HT difficult to control, but from this single case it would seem that with adequate evaluation, care and hemodynamic control, as illustrated by the evolution and outcome of this pregnancy, both hemodynamic status and pregnancy may progress unconventionally where mult.drug antihypertensive regime is neither efficient nor tolerable, provided it is previously hypertensive patient who becomes pregnant with low renin values.

ACKNOWLEDGEMENT
Dr. M. Oliveros-Palacios is at the present time at Departamento Médico, Lagoven, Caracas, Venezuela. Dr. Bernardo Rodriguez-Iturbe’s helpful suggestions are appreciated. Br. José A. Colina provided help by typing the manuscript.

REFERENCES
2- COLINA-CHOURIJO J., GODOY N., OLIVEROS-PALACIOS M., AROCHA I.: Long-term (3 years) sustained antihypertensive and metabolic actions of nitrendipine in...
severe, complicated, and resistant hyperten-
3. COLINA-CHOURIO J., OLIVEROS-
PALACIOS M.CH., GODAY N.: Ni-
trendipine: a slow calcium channel
blocking agent that reduces high
blood pressure and promotes renal
hormones and function changes in
severe hypertension. J Hypertens
4. DEWIT TM.: Antihypertensive drugs
in pregnancy. Br Med J 291:365-
5. ESPER R.J., ESPER R.C., BAGUJO
H., CASTRO J.M., ROHWEDDER
R.W., MENNA J.: Long-term effec-
tiveness of BAY c5009- Nitrendipine
in the treatment of mild to moderate
arterial hypertension. J Cardiovasc
6. FLECKENSTEIN A., FREY M., ZORN
J., FLECKENSTEIN-GRUN G.: Ex-
perimental basis of the long-term
therapy of arterial hypertension with
calcium antagonists. Am J Cardiol
7. FRIEDMAN W.H., WEINBERG P.,
PEDEL H.B., KIMBLE B., CHARLAP
S., BEARN.: Calcium entry blockers
for the treatment of severe hyperten-
sion and hypertensive crisis. Am J
8. GIFFORD R.W., TARAIZER C.: Resis-
tant hypertension: diagnosis and
management. Ann Int Med 88:661-
blood flow. Obstet Gynecol Annu
10. HOFFLER R., STOEPEL K.: Ni-
trendipine in hypertension that is
difficult to control. J Cardiovasc
11. KIOWSKI W., BUHLER F.R.,
FADAYOMI M.O.: Age, race, blood
pressure and resin: Predictors for
antihypertensive treatment with cal-
cium antagonists. Am J Cardiol
12. LOHTZENHEIZER R.D., EPSTEIN
M.: Calcium antagonists and the kid-
13. NUSSBERGER J., BUCHER H.,
SCHMID J.: The control of plasma
aldosterone in mother and newborn
in labour and in the postnatal per-
iod. Research on steroids. p. 547-
Amsterdam (Holland). 1977.
14. OLIVEROS-PALACIOS M.CH.,
GODOY-GODOY N., COLINA-
CHOURIO J.A.: Effects of corticoster-
on blood pressure, renin-angioten-
sin-aldosterone and urinary kalli-
krein. Am J Cardiol 67:157-161,
15. ORLANDI C., MARLETTI M.G.,
CASSANI A.: Treatment of hyper-
tension during pregnancy with the cal-
cium antagonist verapamil. Curr
16. ROTHBERG A.D., LORENZ R.: Can
captopril cause death or neonatal
renal failure?. Pediatr Pharmacol
17. SCHUBIGER G., FLURY G.,
MUSSEMBER J.: Enalapril for preg-
nancy-induced hypertension: acute
renal failure in a neonate. Ann
18. SWALES J.D., WAGGERT A., RUS-
SELL G.J., BING R.S., POHL J.E.S.,
THURSTON H.: Treatment of refrac-
tory hypertension. Lancet 1: 894-
896, 1982.
19. VAN ZWIETEN P.A., VAN MEEL
J.C.A., TIMMERMANS P.B.M.W.M.: Pharn-
cologically of calcium entry
blockers: interaction with vascular
alpha-adrenoceptors. Hypertension
5 (Suppl 2):8-17, 1983.
20. WALTERS B.N.J., REDMAN L.W.G.: Treat-
ment of severe pregnancy asso-
ciated hypertension with the cal-
cium antagonist nifedipine. Br J Obstet